{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T04:32:50Z","timestamp":1783053170905,"version":"3.54.6"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,8,19]],"date-time":"2018-08-19T00:00:00Z","timestamp":1534636800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["111241"],"award-info":[{"award-number":["111241"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00262-018-2229-6","type":"journal-article","created":{"date-parts":[[2018,8,18]],"date-time":"2018-08-18T23:37:26Z","timestamp":1534635446000},"page":"813-822","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Monitoring of patients with metastatic melanoma treated with immune checkpoint inhibitors using PET\u2013CT"],"prefix":"10.1007","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0338-9472","authenticated-orcid":false,"given":"Antonia","family":"Dimitrakopoulou-Strauss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,19]]},"reference":[{"key":"2229_CR1","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","volume":"14","author":"JJ Luke","year":"2017","unstructured":"Luke JJ, Flaherty KT, Ribas A, Long GV (2017) Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol 14:463\u2013482","journal-title":"Nat Rev Clin Oncol"},{"key":"2229_CR2","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Nevns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A, Keynote-006 Investigators (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521\u20132532","journal-title":"N Engl J Med"},{"key":"2229_CR3","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O\u2019Dav S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412\u20137420","journal-title":"Clin Cancer Res"},{"key":"2229_CR4","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"2229_CR5","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1158\/1078-0432.CCR-13-0895","volume":"19","author":"M Nishino","year":"2013","unstructured":"Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS (2013) Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res 19:3936\u20133943","journal-title":"Clin Cancer Res"},{"key":"2229_CR6","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1200\/JCO.2015.64.0391","volume":"34","author":"FS Hodi","year":"2016","unstructured":"Hodi FS, Hwu W-J, Kefford R, Weber JS, Daud A, Hamid O, Patnaik A, Ribas A, Robert C, Gangadhar TC, Joshua AM, Hersey P, Dronca R, Joseph R, Hille D, Xue D, Li XN, Kang P, Ebbinghaus S, Perrone A, Wolchok JD (2016) Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol 34:1510\u20131517","journal-title":"J Clin Oncol"},{"key":"2229_CR7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Liti\u00e8re S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, de Vries EG (2017) iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18:143\u2013152","journal-title":"Lancet Oncol"},{"key":"2229_CR8","first-page":"623","volume":"32","author":"LG Strauss","year":"1991","unstructured":"Strauss LG, Conti PS (1991) The applications of PET in clinical oncology. J Nucl Med 32:623\u2013648","journal-title":"J Nucl Med"},{"key":"2229_CR9","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","volume":"35","author":"H Young","year":"1999","unstructured":"Young H, Baum R, Cremerius U et al (1999) Measurement of clinical and subclinical tumour response using (18F)-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35:1773\u20131782","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"2229_CR10","doi-asserted-by":"publisher","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1):122S\u2013150S","journal-title":"J Nucl Med"},{"key":"2229_CR11","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.2967\/jnumed.112.109421","volume":"53","author":"F Kraeber-Bodere","year":"2012","unstructured":"Kraeber-Bodere F, Carlier T, Naegelen VM, Shochat E, Lumbroso J, Trampal C, Nagarajah J, Chua S, Hugonnet F, Stokkel M, Gleeson F, Tessier J (2012) Differences in the biologic activity of 2 novel MEK inhibitors revealed by 18F-FDG PET: analysis of imaging data from 2 phase I trials. J Nucl Med 53:1836\u20131846","journal-title":"J Nucl Med"},{"key":"2229_CR12","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1200\/JCO.2011.39.1938","volume":"30","author":"GA McArthur","year":"2012","unstructured":"McArthur GA, Puzanov I, Amaravadi R, Ribas A, Chapman P, Kim KB, Sosman JA, Lee RJ, Nolop K, Flaherty KT, Callahan J, Hicks RJ (2012) Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol 30:1628\u20131634","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"2229_CR13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00259-017-3691-7","volume":"44","author":"ANM Wong","year":"2017","unstructured":"Wong ANM, McArthur GA, Hofman MS, Hicks RJ (2017) The advantages and challenges of using FDG PET\/CT for response assessment in melanoma in the era of targeted agents and immunotherapy. Eur J Nucl Med Mol Imaging 44(Suppl 1):67\u201377","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2229_CR14","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s00259-014-2944-y","volume":"42","author":"C Sachpekidis","year":"2015","unstructured":"Sachpekidis C, Larribere L, Pan L, Haberkorn U, Dimitrakopoulou-Strauss A, Hassel JC (2015) Predictive value of early 18F-FDG PET\/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study. Eur J Nucl Med Mol Imaging 42:386\u2013396","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2229_CR15","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1007\/s00259-017-3870-6","volume":"45","author":"H Anwar","year":"2018","unstructured":"Anwar H, Sachpekidis C, Winkler J, Kopp-Schneider A, Haberkorn U, Hassel JC, Dimitrakopoulou-Strauss A (2018) Absolute number of new lesions on 18F-FDG PET\/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. Eur J Nucl Med Mol Imaging 45:376\u2013383","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2229_CR16","doi-asserted-by":"publisher","first-page":"340","DOI":"10.2967\/jnumed.109.070946","volume":"51","author":"A Ribas","year":"2010","unstructured":"Ribas A, Benz MR, Allen-Auerbach MS, Radu C, Chmielowski B, Seja E, Williams JL, Gomez-Navarro J, McCarthy T, Czernin J (2010) Imaging of CTLA4 blockade-induced cell replication with 18F-FLT PET in patients with advanced melanoma treated with tremelimumab. J Nucl Med 51:340\u2013346","journal-title":"J Nucl Med"},{"key":"2229_CR17","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.2967\/jnumed.116.188839","volume":"58","author":"SY Cho","year":"2017","unstructured":"Cho SY, Lipson EJ, Im HJ, Rowe SP, Gonzalez EM, Blackford A, Chirindel A, Pardoll DM, Topalian SL, Wahl RL (2017) Prediction of response to immune checkpoint inhibitor therapy using early-time-point 18F-FDG PET\/CT imaging in patients with advanced melanoma. J Nucl Med 58:1421\u20131428","journal-title":"J Nucl Med"},{"issue":"1","key":"2229_CR18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13550-016-0216-5","volume":"6","author":"CM Breki","year":"2016","unstructured":"Breki CM, Dimitrakopoulou-Strauss A, Hassel J, Theoharis T, Sachpekidis C, Pan L, Provata A (2016) Fractal and multifractal analysis of PET\/CT images of metastatic melanoma before and after treatment with ipilimumab. EJNMMI Res 6(1):61","journal-title":"EJNMMI Res"},{"issue":"6165","key":"2229_CR19","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","volume":"342","author":"J Couzin-Frankel","year":"2013","unstructured":"Couzin-Frankel J (2013) Breakthrough of the year 2013\u2014cancer immunotherapy. Science 342(6165):1432\u20131433","journal-title":"Science"},{"key":"2229_CR20","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/ITT.S126227","volume":"6","author":"JM Yoest","year":"2017","unstructured":"Yoest JM (2017) Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review. Immunotargets 6:73\u201382","journal-title":"Immunotargets"},{"key":"2229_CR21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ejca.2018.03.006","volume":"96","author":"A Mekki","year":"2018","unstructured":"Mekki A, Dercle L, Lichtenstein P, Marabelle A, Michot JM, Lambotte O, Le Pavec J, De Martin E, Balleyguier C, Champiat S, Ammari S (2018) Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. Eur J Cancer 96:91\u2013104","journal-title":"Eur J Cancer"},{"key":"2229_CR22","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3389\/fonc.2017.00233","volume":"7","author":"CAC Jessurun","year":"2017","unstructured":"Jessurun CAC, Vos JAM, Limpens J, Luiten RM (2017) Biomarkers for response of melanoma patients to immune checkpoint inhibitors: a systematic review. Front Oncol 7:233","journal-title":"Front Oncol"},{"key":"2229_CR23","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1001\/jamaoncol.2016.0639","volume":"2","author":"AG Sacher","year":"2016","unstructured":"Sacher AG, Gandhi L (2016) Biomarkers for the clinical use of PD-1\/PD-L1 inhibitors in non-small-cell lung cancer: a review. JAMA Oncol 2:1217\u20131222","journal-title":"JAMA Oncol"},{"key":"2229_CR24","doi-asserted-by":"publisher","first-page":"538","DOI":"10.2967\/jnumed.116.177659","volume":"58","author":"AT Mayer","year":"2107","unstructured":"Mayer AT, Natarajan A, Gordon SR, Maute RL, Mc Cracken MN, Ring AM, Weissman IL, Gambhir SS (2107) Practical immuno-PET radiotracer design considerations for human immune checkpoint imaging. J Nucl Med 58:538\u2013546","journal-title":"J Nucl Med"},{"key":"2229_CR25","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s11307-017-1060-3","volume":"19","author":"A Natarajan","year":"2017","unstructured":"Natarajan A, Mayer AT, Reeves RE, Nagamine CM, Gambhir SS (2017) Development of novel ImmunoPET tracers to image PD-1 checkpoint expression on tumor-infiltrating lymphocytes in a humanized mouse model. Mol Imaging Biol 19:903\u2013914","journal-title":"Mol Imaging Biol"},{"key":"2229_CR26","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.2967\/jnumed.114.153338","volume":"56","author":"R Tavare","year":"2015","unstructured":"Tavare R, McCracken MN, Zettlitz KA, Salazar FB, Olafsen T, Witte ON, Wu AM (2015) Immuno PET of Murine T cell reconstitution postadoptive stem cell transplantation using anti-CD4 and anti-CD8 cys-diabodies. J Nucl Med 56:1258\u20131264","journal-title":"J Nucl Med"},{"key":"2229_CR27","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.1158\/0008-5472.CAN-15-2784","volume":"76","author":"S Mall","year":"2016","unstructured":"Mall S, Yusufu N, Wagner R, Klar R, Bianchi H, Steiger K, Straub M, Audehm S, Laitinen I, Aichler M, Peschel C, Ziegler S, Mustafa M, Schwaiger M, D\u00e1llesandria C, Krackhardt AM (2016) Immuno\u2013PET imaging of engineered human T cells in tumor. Cancer Res 76:4113\u20134123","journal-title":"Cancer Res"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2229-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-018-2229-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2229-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T03:38:20Z","timestamp":1569296300000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-018-2229-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,19]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["2229"],"URL":"https:\/\/doi.org\/10.1007\/s00262-018-2229-6","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,19]]},"assertion":[{"value":"9 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The author declares that she has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable. This is a review and not an original paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable. This is a review and not an original paper. All patients agreed on the publication of their images.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}